<DOC>
	<DOCNO>NCT00827541</DOCNO>
	<brief_summary>This study evaluate safety tigecycline patient complicate intra-abdominal infection ( cIAI ) complicate skin soft tissue infection ( cSSTI ) real practice usual hospital set patient ' condition , order ass `` real incidence '' adverse event related tigecycline patient .</brief_summary>
	<brief_title>Post-Authorization Study Evaluating Safety Of Tigecycline</brief_title>
	<detailed_description>Since around 50 patient include Spanish center involve Phase III Tygacil clinical development program , basis recruitment capacity center within predefined time window number patient consent enrolled study , total number patient estimate enrol study 500 . With sample size , possible obtain precise estimation incidence particular type adverse event .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Skin Diseases</mesh_term>
	<mesh_term>Intraabdominal Infections</mesh_term>
	<mesh_term>Soft Tissue Infections</mesh_term>
	<mesh_term>Skin Diseases , Infectious</mesh_term>
	<mesh_term>Tigecycline</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<criteria>Informed consent sign patient prior study entry . 18 year age old screen visit . Patients cIAI cSSTI . Patients go give previous 48 hour least dose tigecycline treat infection . In opinion investigator , patient able comply requirement protocol . Known hypersensibility tigecycline . Females pregnant , breast feeding , risk pregnancy use medically acceptable form contraception . Use investigational drug within four week screen visit . Uncooperative patient history poor compliance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2011</verification_date>
	<keyword>tigecycline</keyword>
	<keyword>complicate intra-abdominal infection ( cIAI )</keyword>
	<keyword>complicate skin soft tissue infection ( cSSTI ) .</keyword>
</DOC>